Interv Akut Kardiol. 2019;18(3):166-168

AUGUSTUS: a major step towards proper treatment after PCI in the setting of atrial fibrillation

Ivo Varvařovský
Kardiologické centrum AGEL, Pardubice

The AUGUSTUS trial showed superiority of non-vitamin K oral anticoagulant (NOAC) over warfarin for PCI treatment of patients
with atrial fibrillation as well as defined the real position of aspirin in the treatment of these patients. Apixaban and clopidogrel
have been shown to be the best choice for most of the patients, with aspirin being considered only for a minority with a very
high ischaemic risk.

Keywords: atrial fibrillation, PCI, apixaban

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. AUGUSTUS: a major step towards proper treatment after PCI in the setting of atrial fibrillation. Interv Akut Kardiol. 2019;18(3):166-168.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dewilde WJ, Oirbans T, Verheugt FW. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115. Go to original source...
    2. Gibson CM, Mehran R, Bode C. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434. Go to original source...
    3. Cannon CP, Bhatt DL, Oldgren J. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513-1524. Go to original source...
    4. Lopes RD, Heizer G, Aronson R. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509-1524. Go to original source...
    5. Neumann FJ, Sousa-Uva M, Ahlsson A. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.